MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.21
+0.26
+2.16%
Opening 15:12 01/20 EST
OPEN
11.93
PREV CLOSE
11.95
HIGH
13.00
LOW
11.93
VOLUME
33.37K
TURNOVER
--
52 WEEK HIGH
45.82
52 WEEK LOW
11.61
MARKET CAP
361.74M
P/E (TTM)
-5.2668
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 2d ago
Pulse biosciences expects preliminary 4Q and FY21 revenues below the consensus
Pulse Biosciences (NASDAQ:PLSE) preliminary unaudited FY21 revenue is expected to be in the range of $1.3M to $1.4M (consensus of $1.44M). 4Q preliminary unaudited revenue expected of approximately $750K (consensus of
Seekingalpha · 01/11 12:31
BRIEF-Pulse Biosciences Announces Preliminary Fourth Quarter And Full Year 2021 Financial And Operational Results
reuters.com · 01/11 12:06
Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc
Investment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, acco...
GuruFocus.com · 12/28/2021 07:38
What Type Of Shareholders Own The Most Number of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
The big shareholder groups in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) have power over the company. Institutions often...
Simply Wall St. · 12/17/2021 14:20
Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks · 11/25/2021 15:00
Pulse Biosciences to Participate in the Stephens Annual Investment Conference
HAYWARD, Calif., November 18, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Stephens A...
Business Wire · 11/18/2021 21:05
HC Wainwright & Co. Maintains Buy on Pulse Biosciences, Lowers Price Target to $43
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and lowers the price target from $46 to $43.
Benzinga · 11/16/2021 14:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PLSE stock price target is 37.00 with a high estimate of 43.00 and a low estimate of 28.00.
High43.00
Average37.00
Low28.00
Current 12.21
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 71
Institutional Holdings: 4.19M
% Owned: 14.12%
Shares Outstanding: 29.63M
TypeInstitutionsShares
Increased
19
816.14K
New
7
445.36K
Decreased
15
224.26K
Sold Out
5
75.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.38%
Healthcare Equipment & Supplies
+0.52%
Key Executives
Non-Executive Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Director
Mitchell Levinson
Director
Shelley Spray
Independent Director
Manmeet Soni
Independent Director
Richard van den Broek
No Data
  • All
  • Financials
  • Insiders
More
About PLSE
Pulse Biosciences, Inc. is a novel bioelectric medicine company. The Company's Nano-Pulse Stimulation (NPS) technology platform is designed to send energy pulses to cells in order to alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum, without disrupting extracellular tissue. Its commercial product CellFX System is is designed to function on the basis of a non-thermal mechanism of action in a biophysical disruption brought about by the tunable speed and amplitude of NPS pulses interacting with the physical structure of cells. The CellFX System includes a multi-use handpiece and an initial suite of five single use dermatology treatment tips.

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.